Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Post by InitiumMMXXIIIon Jan 03, 2025 8:14pm
92 Views
Post# 36387030

Where are the links?

Where are the links?Come on, boyz, post the links, show us some evidence that xB3 failed.

We all can prove that Bioasis failed, but proving xB3 failed is a whole other thing.

I agree that there is significant likelihood that xB3 doesn't work, or at least has issues sufficient to cause work to stop.

You guys thiunk that I'm trying to convince you and other shareholders of somethinbg else.

WRONG!!!!!!!

If mangement at any time in Bioasis' history knew that xB3 had killer problems and didn't tell us then I thuink they should be fully exposed for that. Until the very end, they expressed confidence in xB3. That confidence is still being expressed to a large degree in the description of Bioasis and xB3 at the top of this very Stockhouse page. They were mantaining that position until the moment they all resigned from the BoD and their offices.

And, yes, I do knoiw a heck of a lot more than you guys do about this stuff. No brag. Just a fact. But as is obvious, I also reveal the stuff I don't know, including whether xB3 can never work as a drug delivery agent using receptor-mediated transcytosis.

Unlike you guys, I will not say, WITHOUT PROOF, that xB3 does not work. No public evidence has be issued to show that it does not work. There is some public evidence that it does work. I'm really suspicious that it doesn't work, but I refuse to say that for certain. If xB3 didn't (doesn't) work, then we (WE, all of us!!!) must consider that we may have been purposefully deceived about the issue.

What other reasons might there be for Chiesi cancelling their agreement with Bioasis? Kinda obvious, really.

jd
<< Previous
Bullboard Posts
Next >>